ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Entera Bio Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.94+0.26 (+9.70%)
Close on Oct 19, 2026
- Market cap
- $148.33M
- P/E (TTM)
- 11.8
- Dividend yield
- –
Share price
+$0.59 (+25.11%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Entera Bio Ltd. saw revenue fall 100.0% to $0 over the twelve months to Jun 30, 2026. Free cash flow was -$10.96M.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$14.40M
TTM Q2 2026
Free cash flow
-$10.96M
TTM Q2 2026
EPS, diluted
$0.25
0.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $148.33M
- P/E ratio
- 11.8
- Price to sales
- –
- Price to book
- 20.41
- Dividend yield
- –
- Free cash flow yield
- -7.39%
Fundamentals
- Revenue
- $0
- Net income
- -$17.03M
- EPS, diluted
- $0.25
- Free cash flow
- -$10.96M
- Book value per share
- $0.14
- Diluted shares
- 50M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
$0-100.0% YoY
Gross profit
$0
Operating income
-$14.40M
Net income
-$17.03M
EPS, diluted
–
Free cash flow
-$10.96M
Reported periodTrailing twelve months